First in human implantation of a novel transfemoral self-expanding transcatheter heart valve to treat pure aortic regurgitation

EuroIntervention Journal

The first case of a novel JenaValve design using the transfemoral approach in a 78 year old female patient with pure aortic regurgitation is described in this article.

Transcatheter aortic valve implantation (TAVI) is an established treatment option for severe aortic stenosis in patients at high or prohibitive surgical risk. In addition, TAVI has also been used to treat pure aortic regurgitation (AR). Several cases or series have been reported using various transcatheter heart valves (THVs). Because most THVs usually need a certain extent of calcification for anchoring, their use in native primary AR is limited.

The implantation was successfully performed n this case with excellent haemodynamics and good clinical outcome at 6 months follow up. The technology is especially appealing in non-calcified anatomies due to the clipping mechanism that has been previously utilized in the transapical design.

Read full article


Supported by


Ulrich Schaefer, Johannes Schirmer, Schofer Niklas, Eva Harmel, Florian Deuschl and Lenard Conradi